SMShubhrajit Mantry

Shubhrajit Mantry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shubhrajit Mantry has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Microplastics and gut dysbiosis: links to cancer inflammation

    by Joy Das, Utpal Bhui, Samy Selim, Sathvik Belagodu Sridhar, Ashok Kumar Sah, Anas Islam, Uttam Prasad Panigrahy, Shubhrajit Mantry, Mohd. Tariq, Biplab Debnath, et al.

  • Circular RNAs at the crossroads of oxidative stress: novel targets for precision therapeutics

    by Vijay Singh, Rashmi Sinha, Joy Das, Anas Islam, Sathvik Belagodu Sridhar, Uttam Prasad Panigrahy, Shubhrajit Mantry, Haleema Shahin, Krishnendu Adhikary, Radheshyam Pal, et al.

  • Modulating drug response through the gut microbiome: pathways to precision therapy

    by Nitish Kumar, Joy Das, Murugesan Vanangamudi, Naheed Mojgani, Anas Islam, Sathvik Belagodu Sridhar, Himanshu Sharma, Sanjesh Kumar, Uttam Prasad Panigrahy, Shubhrajit Mantry, et al.

    The mutual association formed between the gut flora and the biological host is pivotal, mainly for drug action. Various examination has spotlighted the potential consequences of the gut microbiome on drug efficacy, revealing its role in controlling metabolism in the body. Furthermore, reciprocal engagement has been examined to investigate how pharmaceutical agents influence the composition of the gut microbiome. This paper emphasizes the intricate relationship between pharmacology and environmental microbiology, directing the extensive significance of pharmaceutical agents on health by controlling the gut microbial consortium. One main highlight of this review is to determine the differences observed in populace as a result of drugs, which is a crucial component in boosting personalized treatment approaches and intensifying therapeutic findings. Apart from their function in drug metabolization, the gut microbiota is disclosed as a source of metabolic products that can alter drug action. These microbially-derived metabolites could notably effect drug results and changes the body’s physical mechanisms. The investigation suggests utilizing metabolomics to disclose the complications of gut microbiota–drug interactions. Several latest analytical strategies provide an effective tool for deciphering the complicated association among microbiome-generated fragments and pharmaceutical products, providing detailed understanding into this interesting connection. Graphical abstract


  • The melatonin-microbiome axis: a new frontier in gut health for the immunomodulatory, antioxidant and anti-inflammatory properties

    by Priyanka Gupta, Biplab Debnath, Sumel Ashique, Mohhammad Ramzan, Sabina Yasmin, Eman Shorog, Shubhrajit Mantry, Mohd Tariq, Sathvik Belagodu Sridhar, Uttam Prasad Panigrahy, et al.

    Melatonin, primarily produced by the pineal gland, is also synthesized in significant amounts within the gastrointestinal (GI) tract, where its presence surpasses that in the brain. While the pineal gland secretes melatonin to regulate circadian rhythms and promote sleep, gut-derived melatonin plays a crucial role in regulating motility, protecting the mucosa from oxidative stress, and modulating immune function. The interaction between melatonin and gut microbiota is gaining significant attention, as melatonin can influence specific gut microbes and functions, potentially altering the intestinal microbiota, which is essential for maintaining overall health. This review explores the bidirectional relationship between melatonin and gut microbiota, highlighting its influence on microbial composition, intestinal barrier function, microbial metabolism, and immune modulation. Additionally, melatonin indirectly affects the gut microbiota through circadian regulation, further reinforcing its critical role in gut homeostasis. The presence of melatonin receptors in the gut and its interaction with microbial biofilms underline its importance in maintaining a balanced gut environment. Given these multifaceted roles, melatonin emerges as a promising therapeutic candidate for managing gut-related disorders such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and metabolic dysregulation. Despite its promising therapeutic potential, several aspects of melatonin-gut microbiome interactions remain unexplored, necessitating further research into its molecular mechanisms and clinical applications. This review provides an in-depth exploration of melatonin’s role in gut microbiome regulation, its therapeutic implications, and future research directions. Graphical abstract


  • Exosome as emerging therapeutic platform for wound healing: Current status, advancement and future crosstalk

    by Sumel Ashique, Ashish Garg, Anas Islam, Krishnendu Adhikary, Shubhrajit Mantry, Sanjesh Kumar, Biplab Debnath, Sabina Yasmin, Reyaz Hassan Mir, Yousuf Ansari